3 infants died in New York of congenital syphilis. Here's what you need to know
The deaths occurred outside of New York City and are part of "a concerning rise" in congenital syphilis cases in the state and across the nation, according to the NYDOH.
Cases of congenital syphilis have been rising nationwide in recent years, according to data from the Centers for Disease Control and Prevention (CDC). In 2023, there were more than 3,800 cases reported, a 106% increase from 2019 and the highest annual case count on record since 1994.
MORE: Newborn syphilis cases at 'dire' levels as analysis shows tenfold increase in last decade: CDC
Public health experts told ABC News that congenital syphilis is largely preventable and, when left untreated, it can be dangerous, or even deadly.
"What's so devastating is that [congenital syphilis] is very preventable," Dr. Elizabeth Partridge, associate clinical professor of pediatric infectious disease at UC Davis Children's Hospital, told ABC News. "It's an epidemic of congenital syphilis and infections in women of childbearing age."
What is congenital syphilis?
Syphilis is a common sexually transmitted infection (STI). It starts as a painless sore where the infection entered the body.
This infection is easily treated with an antibiotic when caught early. If left untreated, it often progresses, over weeks or months, to a worsening rash that may be accompanied by symptoms such as fever, muscle aches, headache and fatigue, according to the CDC.
Symptoms can resolve on their own over time but without treatment, syphilis enters a "latent stage," or asymptomatic stage, that can last for years and may progress further to a "tertiary stage" that can impact multiple organs in the body.
Congenital syphilis occurs when a pregnant person with untreated syphilis passes the infection to their baby either during pregnancy or at birth. It can be treated with antibiotics and it's best to treat as soon as possible to prevent more severe complications of the disease.
The CDC recommends that all pregnant people get tested for syphilis at their first health care visit after learning they are pregnant. Some places with higher rates of this infection may recommend additional screening throughout pregnancy and at birth.
Partridge said women of childbearing age who have barriers to prenatal care are at greater risk because they may miss out on syphilis screening.
"I see a lot of times that moms don't get those full screenings done, they don't have access to that kind of prenatal care. And that, to me, is just tragic because if moms can get screened, then they can get treated," Partridge said.
Why can it be so dangerous?
Congenital syphilis can lead to miscarriage, stillbirth, low birth weight, prematurity or infant death soon after birth, according to the CDC.
Babies born with this disease can have deformed bones, low blood counts, jaundice and organ dysfunction, including problems with the brain and nervous system or enlarged liver and spleen. Partridge says common symptoms of congenital syphilis are known but many aren't obvious at birth.
MORE: Mississippi sees 10-fold increase in babies born with syphilis since 2016: Report
"I think up to 70% of babies who may meet the case definition for congenital syphilis are actually asymptomatic, which makes diagnosing it quite challenging," Partridge said.
Without treatment, babies who are asymptomatic at birth can begin to show signs of the disease weeks, months or years later.
"If they're undetected, if the infants are left untreated, they go on to develop what we call later sequelae, and that's when you see deafness, blindness, developmental delay, the quite devastating illness," Partridge said.
Why is congenital syphilis on the rise?
Dr. James McDonald, commissioner of the NYDOH, told ABC News that the three newborn deaths from syphilis are concerning because it's uncommon to see infant deaths from the condition.
McDonald said that New York State has seen 21 cases of congenital syphilis so far this year, compared to 36 cases all of last year.
"Keep in mind, these may sound like big numbers, but for upstate New York, they are big numbers," he said. "What concerns me, though, is it should be zero."
Kristin Wall, an associate professor of epidemiology at Emory University's Rollins School of Public Health, told ABC News the U.S. has seen a steady rise in congenital syphilis cases over the last 10 years. This is despite decreases in cases of chlamydia and gonorrhea, according to CDC data.
She said that there are racial/ethnic disparities when it comes to the populations experiencing the highest rates of congenital syphilis.
"So the highest rates we're seeing are in Native Americans, American Indians, Alaska Natives, Hispanic populations and Black populations," Wall said. "And I think it's really important to think about access to care barriers as one of the big reasons that we're seeing these increasing rates in certain populations."
Barriers can include lack of insurance or lack of transportation as well as mistrust of the medical system due to past prejudices, according to Wall.
How to drive down rates of congenital syphilis
Wall said half of cases are occurring among patients who are receiving prenatal care, but are missing timely and appropriate treatment, and the other half are occurring in people who are not engaged in care at all.
For those who are receiving prenatal care, Wall said there is a push to implement point-of-care testing, meaning testing outside of a traditional clinical laboratory, often at the patient's bedside.
Delays in waiting for laboratory test results to come back and then trying to recontact the patient can lead to delays in delivering a diagnosis or administering care, Wall said.
MORE: FDA authorizes 1st over-the-counter, at-home test for syphilis
"A very exciting development to address that is the point of care syphilis testing, where you have a patient right in front of you, you're able to administer that test, get test results in 20, 30 minutes, and administer directly observed treatment right there, without sending, you know, your patient away," she said.
For the patients who are not receiving care, Wall said it's important to work with community partners to enter underserved communities and spread awareness, as well as make sure men and women are getting tested to prevent cases from occurring in the first place.
McDonald said that as part of an effort to eliminate syphilis from pregnancy, New York State requires three syphilis screenings for pregnant people.
"When someone's pregnant, they're supposed to be checked for syphilis three times, one when they have their first visit, the second time around the third trimester, and then the third time is where they give birth," he said. "Part of our message to health care providers is: ensure people are being screened appropriately."
He also encouraged people to practice safe sex to prevent the spread of STIs, including the use of condoms.
Jade A. Cobern, MD, MPH, is board-certified in pediatrics and general preventive medicine, and is a medical fellow of the ABC News Medical Unit.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025
24/7 Market News Issues Corrected Information on Previously issued Press Release with same title DENVER, Aug. 14, 2025 (GLOBE NEWSWIRE) -- a pioneer in digital media dedicated to the swift distribution of financial market news and corporate information, spotlights LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT), a clinical-stage pharmaceutical company focused on developing novel cancer therapies by targeting the modulation of key cellular pathways. 2H 2025 is shaping up to be a defining year for LIXTE. With a focus on its lead compound LB-100, a first-in-class small molecule inhibitor of protein phosphatase 2A (PP2A), a master regulator of cell signaling and DNA damage response. By inhibiting PP2A, LB-100 sensitizes tumors to DNA-damaging agents, including chemotherapy, radiation, and immunotherapy, LIXTE is targeting high-unmet needs in the $200 billion global oncology market (Grand View Research, 2025 projection). Potential upcoming catalysts in 2025, including a first trial result, position LIXTE as a potential disruptor in resistant cancers, where traditional treatments fail due to limited efficacy and toxicity. Upcoming Catalysts: Anticipated Trial Results in 2H 2025 1B/2 Trial – Ovarian Clear Cell Carcinoma (OCCC) Ovarian clear cell carcinoma is an aggressive and chemoresistant subtype of epithelial ovarian cancer, accounting for ~5–10% of all ovarian malignancies but disproportionately contributing to ovarian cancer mortality. The Phase 1B/2 study of LB-100 plus the checkpoint inhibitor dostarlimab (GSK) is designed leverage LB-100's synergistic enhancement of immune checkpoint blockade. Status: Enrolled, with interim safety completed Upcoming Milestone: Preliminary safety and efficacy data expected Q4 2025 Potential Market Impact: Global OCCC treatment market is projected to exceed $750 million by 2028 due to rising incidence and limited targeted therapies 1B/2 Trial – Advanced Soft Tissue Sarcoma (STS) Soft tissue sarcomas are a diverse and difficult-to-treat group of cancers arising from connective tissues. For patients with advanced or metastatic disease, prognosis remains Phase 1B/2 study evaluates LB-100 in combination with doxorubicin, the current standard of care, in patients with advanced STS. Status: Dose escalation completed. Upcoming Milestone: Safety report Q4 2025 Potential Market Impact: The global STS drug market is estimated to reach $2.1 billion by 2030, driven by the emergence of combination therapies and unmet medical need 1B Trial – Metastatic Microsatellite Stable (MSS) Colon Cancer MSS colon cancer, representing roughly 85% of metastatic colorectal cancer (mCRC), remains unresponsive to checkpoint inhibitors. LIXTE is conducting a Phase 1B trial assessing the safety and activity of LB-100 in combination with+ atezolizumab (Roche) (an ICI), seeking to overcome immune resistance in this cold tumor type. Status: Trial open, first patients recruited Potential Market Impact: The global colorectal cancer therapeutics market is expected to surpass $18 billion by 2030, with MSS disease representing the majority of treatment-resistant cases Platform Potential and Market Opportunity LIXTE's strategy of targeting PP2A to potentiate multiple treatment modalities positions LB-100 as a versatile combination agent with broad applicability across solid tumors. The platform's potential spans oncology subtypes with high unmet need, limited innovation, and growing incidence. Strong IP Position: Multiple issued and pending patents covering composition, methods of use, and combinations Pipeline Expansion: Additional tumor types and investigator-sponsored studies are under review, including glioblastoma. Partnership Potential: Ongoing discussions with academic institutions and biopharma partners for co-development opportunities Contact sales@ for Analyst Report coverage and other investor/public relations services. About LIXTE Biotechnology Holdings, Inc. LIXTE is a clinical-stage pharmaceutical company focused on discovering and developing innovative cancer therapies targeting the protein phosphatase 2A (PP2A) pathway, a previously underexplored avenue in cancer treatment. The company's lead compound, LB-100, is a first-in-class PP2A inhibitor that has demonstrated strong preclinical results and early-stage clinical tolerability. LIXTE is currently advancing proof-of-concept trials in Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer, and Advanced Soft Tissue Sarcoma. More information can be found at: 24/7 MARKET NEWS, INC DisclaimerPlease go to for further LIXT information and LIXT disclosure information. Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company's ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company's ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company's filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law. CONTACT: CONTACT: 24/7 Market News Editor@ in to access your portfolio


New York Times
31 minutes ago
- New York Times
Draft of White House Report Suggests Kennedy Won't Push Strict Pesticide Regulations
A highly anticipated White House report on the health of American children would stop short of proposing direct restrictions on ultraprocessed foods and pesticides, which the health secretary, Robert F. Kennedy Jr., has called major threats, according to a draft of the document that was reviewed by The New York Times. The report, if adopted, would be good news for the food and agriculture industries, which feared far more restrictive proposals than the ones outlined in the draft. Through his 'Make America Healthy Again' movement, Mr. Kennedy has sought to overhaul the nation's diet by pushing those industries to make major changes. The draft includes an array of policy proposals calling for research into topics like electromagnetic radiation, children's oral health, the role of the microbiome and the health effects of air quality and microplastics. It also recommends government action on a wide range of issues, including initiatives to increase breastfeeding rates, address infertility, promote physical activity and educate the public on the effects of vaping. Questions about a possible push for new pesticide regulations were raised in May when the White House released an initial report, from a presidential commission chaired by Mr. Kennedy, that raised strong concerns about possible links between pesticides and childhood diseases. It also linked the dominance of ultraprocessed foods in children's diets to a range of chronic diseases. Those findings touched off tensions between Mr. Kennedy's movement and Republican lawmakers who have traditionally drawn support from powerful agriculture, food and drug lobbyists. The Times obtained the draft of the new report from a former federal official. An industry official confirmed that it was nearly identical to a copy the administration had recently shown the official at the White House. Kush Desai, a White House spokesman, on Thursday would not verify the draft. At this stage, any draft would go through a number of revisions before it is finalized. The document The Times reviewed was labeled 'pre-decisional' and dated Aug. 6. Called the 'Make Our Children Healthy Again Strategy,' the report comes from the commission led by Mr. Kennedy, which includes cabinet secretaries and agency heads from across the government. The White House has not said when the report will be made public, though it was to have been presented to President Trump on Tuesday, the deadline set by Mr. Trump's executive order establishing the 'MAHA Commission.' The final report is expected to be released in the coming weeks. The draft report says that environmental regulators will work with 'food and agricultural stakeholders' to ensure that the public is aware of and confident in existing pesticide review procedures. It described those procedures as 'robust' and did not propose new restrictions. It also says the Trump administration will back research on technologies to try to help farmers reduce pesticide use and on the health effects of Americans' cumulative exposure to chemicals. After the first report was published in May, agriculture groups, including the American Soybean Association and the National Corn Growers Association, urged the Trump administration to listen to farmers as the commission prepared its follow-up report outlining a strategy. The draft reviewed by The Times does not mention how the proposed research and the new policy initiatives would be funded or how much money might be allocated to them. But it says that the Department of Health and Human Services will form a working group to evaluate 'overprescription trends' involving mental health medications, such as S.S.R.I.s and stimulants, for children. It reiterates Mr. Kennedy's pledge to study the 'root causes' of autism. Mr. Kennedy has spent much of his tenure as health secretary characterizing modern American childhood as a state of stress and sickness, with children mainly eating ultraprocessed food, which he has called 'poison,' tethered to screens and reliant on pills and shots. And he has railed against the pharmaceutical industry, which he says exerts undue influence over scientific research, all while the Trump administration has decimated funding for many academic research programs. Mr. Kennedy has also condemned scientific experts. In June, he fired all the members of an influential vaccine advisory panel. The first report, from May, reflected many of Mr. Kennedy's key talking points. It was heavily scrutinized. While some scientists applauded its focus on flaws within the American food system, many noted it misrepresented the scientific consensus on issues like vaccines. The report also cited studies that did not exist. In recent weeks, Mr. Kennedy's aides and allies have publicized what they described as the administration's most significant steps to improve American health. These include persuading some food makers to phase out petroleum-based food dyes, working with several states to remove soda and candy from their food stamp programs and trying to tighten oversight of food additives. The draft reiterates that the administration will continue these efforts. Some researchers have cautioned that such steps may not do much to improve the overall healthfulness of the American food supply. Ultraprocessed foods, which make up about 62 percent of the calories consumed by U.S. children, are explicitly mentioned in the draft of the second report only once, in a line about the administration's effort to define them. The near-omission of ultraprocessed foods from the draft report raises questions about the administration's appetite for regulation, which the food industry is likely to vehemently oppose. The draft does describe prioritizing 'whole, healthy' foods in federal programs like those providing meals in schools. It suggests offering these foods in 'MAHA boxes' for food stamp recipients. The draft touches on a number of other topics, including vaccines, a focus of Mr. Kennedy's. It says the health department will develop a framework for 'Ensuring America has the Best Childhood Vaccine Schedule.' Mr. Kennedy, one of the nation's most prominent vaccine skeptics, recently pledged to overhaul the nation's system to compensate people harmed by vaccines. Earlier this month, he canceled nearly $500 million in contracts for mRNA vaccines. The draft report also suggests that the government will consider developing guidelines that would limit marketing of unhealthy foods directly to children and will more vigorously enforce restrictions around direct-to-consumer drug advertising. It says the Centers for Disease Control and Prevention will update its recommendations on fluoride in water. On Tuesday, Calley Means, a senior adviser to Mr. Kennedy, spoke at a Heritage Foundation event on the role of agriculture in public health, presenting farmers as key players in American health care. 'We are not going to win if the soybean farmers and the corn growers are our enemy,' he said. There are signs that the report, as drafted, could land with a thud among Mr. Kennedy's followers. In July, 500 people, including leaders of advocacy groups aligned with Mr. Kennedy's movement, sent a letter to Mr. Kennedy and other members of the White House commission urging them to ban pesticides like glyphosate. Hundreds of people tied to the MAHA movement, including Vani Hari, a prominent food activist and MAHA influencer, also sent a letter addressed to Mr. Trump on Monday urging him to take action against protections for pesticide manufacturers. Over the first six months of his presidency, Mr. Trump has largely supported Mr. Kennedy's decisions, after urging him during the campaign to 'go wild' on health. This month, though, after Mr. Kennedy canceled the contracts for mRNA vaccines, Mr. Trump told reporters that the mRNA coronavirus vaccine development initiative from his first term, Project Warp Speed, was 'one of the most incredible things ever done in this country.' He said he had scheduled a meeting with Mr. Kennedy to discuss the cancellations. While Mr. Trump convened the commission, and put Mr. Kennedy at the helm, he does not have to follow its guidance. 'Unlike other administrations, we will not be silenced or intimidated by the corporate lobbyists or special interests,' Mr. Trump said in May during an event celebrating the release of the commission's first report. 'I want this group to do what they have to do.' 'In some cases, it won't be nice, or it won't be pretty,' he added, 'but we have to do it.'
Yahoo
32 minutes ago
- Yahoo
Bindi Irwin reveals major health update: 'Felt utterly ashamed'
Bindi Irwin has shared a major health update in her long battle with endometriosis. Taking to Instagram, the Wildlife Warrior shared a selfie, revealing she was "finally" feeling better after undergoing two major surgeries. "13 years of fighting for answers. 51 endometriosis lesions, a chocolate cyst, and my appendix were all removed across two surgeries with [Dr. Seckin]," she began her lengthy caption. "My hernia from giving birth that was unzipping - was taken care of. I can FINALLY say that I'm feeling better. Genuinely healing. I can function in everyday life without wanting to throw up or pass out from the pain. Slowly, slowly gaining my strength back." She continued, "I cannot express the gravity of my emotions as I am beginning to recognise myself again. I felt utterly ashamed as a teenager and young adult being told that my pain was just part of being a woman. I felt lesser. I felt hurt. I felt weak. That is not ok. "Young girls and women shouldn't feel alone with pain in the driver's seat of their lives. We need to take away the stigma of talking about women's health. It's time to have open discussions and make change on a global scale." RELATED: Bindi Irwin has fans in tears with emotional admission about Robert Irwin: 'Sobbing' Robert Irwin shares sweet tribute to sister Bindi Irwin after major surgery: 'Crippling' Bindi Irwin reveals she was 'really sick' for '10-plus years': 'Doctors didn't know' Bindi was previously forced to pull out of the Steve Irwin Gala in Las Vegas in May for surgery, leaving her brother Robert Irwin to host solo. At the time, Robert shared a tribute to his sister that read: "Happy to see you on the up and up, Bindi. You face every hurdle head on, take it in your stride and inspire us." Bindi commented on the post, "One day at a time. Tremendously grateful for your support. You're the best." Bindi Irwin's fans praise her bravery Fans commented on Bindi's post, sharing their admiration, with one person writing, "So proud of you for speaking up and sharing your journey." "I could not think of a better ambassador and role model for women going through this disease than you," another said. "So proud of you and excited for your new beginning, you have bloomed." "Thank you for sharing your story," a third wrote. "We need to keep advocating for every single person out there struggling & being dismissed!" "Thank you for all that you do to advocate for the endometriosis community!" someone else wrote. "You have brought so much awareness to this disease." "I am so sorry you struggled and were in pain," another said. "I am so happy you are healing. You are a very special soul - thank you so much for sharing your story and giving a voice to what affects so many women." Australia Zoo also commented, "Thank you Bindi for your strength and kindness in sharing your personal journey and thus allowing a light to shine on women's health! We LOVE that you are healing, and your bravery is encouraging others to speak out and seek answers." View this post on Instagram A post shared by Not Gonna Lie with Kylie Kelce (@nglwithkylie) What is endometriosis "Endometriosis is a disease in which tissue similar to the lining of the uterus grows outside the uterus," according to the World Health Organisation. "It can cause severe pain in the pelvis and make it harder to get pregnant. "Endometriosis can start at a person's first menstrual period and last until menopause. With endometriosis, tissue similar to the lining of the uterus grows outside the uterus. This leads to inflammation and scar tissue forming in the pelvic region and (rarely) elsewhere in the body." The cause of endometriosis is unknown, and unfortunately, there is no way to prevent it. There is also no cure, and it can only be treated with medication or surgery. Some people will not experience symptoms, but for those who do, it's often pain in the lower part of the belly. SHOP: 🏉 Rugby fan's huge airport surprise after landing in Sydney: 'Surreal' 🛏️ Expert reveals secret to the best night's sleep: 'Wouldn't choose anything else' 🦥 Boody's new range in sizes S to XL are 'the softest sets you'll ever wear': 'Comfy and chic' WHO adds, "It can decrease quality of life due to severe pain, fatigue, depression, anxiety and infertility. Some individuals with endometriosis experience debilitating pain that prevents them from going to work or school." Pain can also be noticeable during a period, during or after sex, or when going to the toilet. Some people also experience: chronic pelvic pain heavy bleeding during periods or between periods trouble getting pregnant bloating or nausea fatigue depression or anxiety Symptoms can improve after menopause, but not always.